Phase I Study of SPH1188-11 in NSCLC
- First Posted Date
- 2017-07-27
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Registration Number
- NCT03231475
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Single Ascending Dose Study of Safety and Tolerability of SPH3127 Tablet in Chinese Healthy Volunteers
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 48
- Registration Number
- NCT03128138
- Locations
- 🇨🇳
The capital medical university affiliated Beijing anzhen hospital, Beijing, Beijing, China
Hydroxytriptolide in Active Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: LTS 1.0mgDrug: PlaceboDrug: LTS 0.25mgDrug: LTS 0.5mg
- First Posted Date
- 2014-07-29
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT02202395
- Locations
- 🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳Changhai Hospital, Shanghai, Shanghai, China
🇨🇳Changzheng Hospital, Shanghai, Shanghai, China
Phase II Clinical Study of Thalidomide in the Treatment of Ankylosing Spondylitis
Phase 2
Completed
- Conditions
- Ankylosing Spondylitis
- Interventions
- First Posted Date
- 2014-07-25
- Last Posted Date
- 2015-11-20
- Lead Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
- Target Recruit Count
- 197
- Registration Number
- NCT02201043
- Locations
- 🇨🇳
The General Hospital of People's Liberation Army, BeiJing, Beijing, China
🇨🇳Sichuan Provincial People's Hospital, Chengdu, Sichuan, China
🇨🇳Xijing Hospital, XiAn, Shanxi, China
© Copyright 2025. All Rights Reserved by MedPath